Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
ID: 341374Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $600K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/341374

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-22-173.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering the Cancer Prevention and Control Clinical Trials Planning Grant Program (R34), aimed at facilitating the development of well-planned clinical trials in cancer prevention and control. This program seeks to address critical information gaps that often arise during the planning phase of clinical trials, focusing on enhancing areas such as cancer-related health behaviors, screening, early detection, and supportive care for cancer survivors. Eligible applicants include a diverse range of institutions, including tribal governments and historically black colleges, with funding available up to $600,000 for projects that include pilot trials over a maximum period of three years. Interested parties should note that the application deadline is September 7, 2025, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAR-22-173-Full-Announcement.html
    PAR-22-173.html
    The Department of Health and Human Services, through the National Cancer Institute (NCI), has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (R34). This program aims to support the development of well-planned clinical trials in cancer prevention and control areas to effectively enhance capabilities in areas such as cancer-related health behaviors, screening, early detection, and supportive care for survivors. The goal is to address information gaps that typically arise during the trial planning phase, which can impede the completion and rigor of clinical trials. Applications for this funding opportunity must focus on activities necessary to enrich the protocol of a full-scale clinical trial, addressing specific planning issues such as study population identification, recruitment strategies, and intervention testing. Eligible applicants include various institutions, nonprofits, and tribal governments, with funding up to $225,000 per year for projects without clinical trials, and up to $600,000 for those that include a pilot trial over a maximum period of three years. Multiple opportunities for applications exist, reinforcing NCI's commitment to innovative research strategies to improve cancer outcomes. The proposal process involves critical adherence to specific guidelines to ensure compliance and successful submission.
    Similar Opportunities
    Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (U34), aimed at facilitating well-planned clinical trials that enhance cancer prevention, treatment, and survivorship care. This funding opportunity seeks to address critical gaps in trial planning by acquiring essential data for finalizing protocols, including feasibility assessments and stakeholder engagement strategies. The program is particularly significant for improving cancer-related health behaviors and outcomes, with grants available up to $600,000 for trials including pilot studies, over a maximum of three years. Interested applicants, including higher education institutions and nonprofit organizations, must submit their proposals by September 7, 2025, and can direct inquiries to OERWebmaster03@od.nih.gov for further information.
    Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering the Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) to support investigator-initiated clinical trials aimed at reducing the burden of cancer. This funding opportunity focuses on enhancing early detection, prevention, healthcare delivery, and survivorship improvements, explicitly excluding studies related to cancer diagnosis or oncologic therapies. Eligible applicants include a diverse range of organizations such as higher education institutions, nonprofits, and tribal organizations, with applications due by 5:00 PM local time on January 5, 2024, and a maximum project period of five years. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the program's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-072.html.
    Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering exploratory grants (R21 Clinical Trial Optional) aimed at advancing cancer control research. This funding opportunity encourages innovative approaches to understanding cancer etiology, behavior modification, and screening techniques, focusing on the early stages of impactful research that can significantly enhance population-based cancer research. Grants will provide up to $275,000 over two years, with a maximum of $200,000 available in a single year, and applications are due by October 8, 2024. Interested applicants can find more information and contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Cancer Prevention Clinical Trials Network (CP-CTNet): CP-CTNet Sites (UG1 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the Cancer Prevention Clinical Trials Network (CP-CTNet) to establish sites for early-phase cancer prevention clinical trials. The initiative aims to develop and conduct trials that assess the safety and efficacy of various preventive agents and interventions targeting specific biological processes associated with cancer development, with a focus on recruiting high-risk participants and conducting multi-institutional studies. This funding underscores the importance of advanced research in cancer prevention, with a total funding amount of $8.75 million annually to support five awards over six years, each with a budget not exceeding $1.375 million. Interested applicants must submit a letter of intent by August 23, 2024, and a complete application by September 30, 2024; for further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Pragmatic Trials across the Cancer Control Continuum" (UG3/UH3), aimed at accelerating the development of evidence-based cancer interventions that reflect the diversity of the U.S. population. This initiative seeks applications that propose interventions designed to improve cancer-related outcomes through pragmatic trial designs, with a particular focus on addressing health disparities among underrepresented populations. The funding opportunity allows for a total of up to $500,000 annually for the UG3 phase and $750,000 for the UH3 phase, with applications accepted until November 17, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    NIAID Clinical Trial Planning Grant (R34 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Allergy and Infectious Diseases (NIAID), has announced a funding opportunity for the Clinical Trial Planning Grant (R34), aimed at supporting the planning and preparation necessary for investigator-initiated clinical trials. This grant encourages applications that focus on high-priority research aligned with NIAID's mission, providing funding of up to $150,000 for activities such as protocol development, study team establishment, and regulatory approvals. The opportunity is open to a diverse range of eligible applicants, including educational institutions, nonprofits, and governmental entities, with applications evaluated based on significance, innovation, and the research environment. Interested applicants should note that the application deadline is May 13, 2026, and can find more information at the provided NIH grants link or by contacting NIH Grants Information at grantsinfo@nih.gov.
    Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities" (R01, Clinical Trial Required). This initiative aims to solicit applications for projects that identify and address barriers to cancer screening and preventive services, particularly in underserved populations, through multi-level interventions involving patients, clinicians, healthcare settings, and community partners. The focus is on developing evidence-based strategies to improve cancer outcomes for groups such as Black Americans, Hispanics, and Native Americans, emphasizing health equity and structured research methodologies. Interested applicants can find more details and submit proposals by January 7, 2027, with the first application due date being October 5, 2023. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov, and further information is available at NIH Grants.
    National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the National Cancer Institute (NCI) for investigator-initiated early phase clinical trials focused on cancer treatment and diagnosis, specifically under the R01 Research Project Grant mechanism (PAR-24-085). This initiative invites research proposals for Phase 0, I, and II clinical trials that align with the missions of various NCI programs, while explicitly excluding Phase III trials. The program aims to advance cancer research by assessing novel therapeutic and diagnostic interventions, improving imaging technologies, and exploring treatment combinations, with applications encouraged from a diverse range of eligible organizations, including educational institutions and non-profits. Interested applicants should note that the submission deadlines begin on January 5, 2024, with the opportunity closing on January 8, 2027. For further details, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-085.html.
    NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced the NCI Small Grants Program for Cancer Research (R03) for the years 2023 to 2025. This funding opportunity is designed to support small-scale research projects on cancer that can be completed within a two-year timeframe and with limited resources, including pilot studies, secondary data analyses, and the development of research methodologies or technologies. Grants of up to $50,000 per year are available to a wide range of eligible applicants, including higher education institutions, nonprofits, and various community organizations. Interested parties should submit their applications electronically via Grants.gov, with the first submission deadline having been January 22, 2023, and subsequent deadlines continuing through 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.